<DOC>
	<DOC>NCT01718522</DOC>
	<brief_summary>The purpose of this registry is to collect the real life data on Sensor Augmented pump therapy usage in type 1 DM patients treated with Medtronic Insulin pumps and countinuous glucose monitoring systems in Germany.</brief_summary>
	<brief_title>RANSuP Registerstudie</brief_title>
	<detailed_description />
	<criteria>patients with signed informed consent Type 1 DM and has been on insulin pump therapy for at least 3 months prior to signature of the informed consent patients use CGM component as part as part of the CSII therapy for a minimum of 1 month participation in any other trial any disease or drug treatment that can interfere with the outcome of sensor usage using CGM in CSII &lt; 3 days/week patients not willing to sign informed consent abuse of alcohol or drugs (exception of nicotine consumption) eating disorder, anorexia, bulimia or other mental disorders</criteria>
	<gender>All</gender>
	<minimum_age>6 Years</minimum_age>
	<maximum_age>69 Years</maximum_age>
	<verification_date>February 2014</verification_date>
</DOC>